EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Tirzepatide for Obesity Treatment and Diabetes Prevention

Ania M Jastreboff iD, Carel W le Roux, Adam Stefanski, Louis J Aronne, Bruno Halpern iD, Sean Wharton, John P H Wilding, Leigh Perreault, Shuyu Zhang, Ramakrishna Battula, Mathijs C Bunck, Nadia N Ahmad und 2 weitere

New England Journal of Medicine · 06.03.2025 · 392 (10) · 958-971

DOI: 10.1056/nejmoa2410819 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 06.03.2025. Verfasst von Ania M Jastreboff und 13 weiteren Autor:innen. Beteiligte Einrichtung: Y-Weight Yale Obesity Research Center, Section of Endocrinology and Metabolism, Department of Medicine, Yale School of Medicine, New Haven, CT. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Obesity, Prediabetic State, Tirzepatide. Die Arbeit wurde bisher 475-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2ObesityPrediabetic StateTirzepatideGlucagon-Like Peptide-1 Receptor AgonistsAdultFemaleHumansMaleMiddle AgedAnti-Obesity AgentsDisease ProgressionDouble-Blind MethodWeight LossBody WeightGastrointestinal DiseasesDose-Response Relationship, Drug

Substanzen

Anti-Obesity AgentsTirzepatideGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Y-Weight Yale Obesity Research Center, Section of Endocrinology and Metabolism, Department of Medicine, Yale School of Medicine, New Haven, CT.
  • Section of Pediatric Endocrinology, Department of Pediatrics, Yale School of Medicine, New Haven, CT.
  • Diabetes Complications Research Centre, University College Dublin, Dublin.
  • Eli Lilly, Indianapolis.
  • Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York.
  • Hospital 9 de Julho, São Paulo.

ORCID-Profile: Ania M Jastreboff, Bruno Halpern

Förderung

  • Eli Lilly and Company

Zitieren

APA

Jastreboff, A. M., le Roux, C. W., Stefanski, A., Aronne, L. J., Halpern, B., Wharton, S., Wilding, J. P. H., Perreault, L., Zhang, S., Battula, R., Bunck, M. C., Ahmad, N. N., Jouravskaya, I., & SURMOUNT-1 Investigators (2025). Tirzepatide for Obesity Treatment and Diabetes Prevention. New England Journal of Medicine, 392(10), 958-971. https://doi.org/10.1056/nejmoa2410819

Vancouver

Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. New England Journal of Medicine. 2025;392(10):958-971. doi:10.1056/nejmoa2410819

BibTeX
@article{Jastreboff2025,
  author = {Jastreboff, Ania M and le Roux, Carel W and Stefanski, Adam and Aronne, Louis J and Halpern, Bruno and Wharton, Sean and Wilding, John P H and Perreault, Leigh and Zhang, Shuyu and Battula, Ramakrishna and Bunck, Mathijs C and Ahmad, Nadia N and Jouravskaya, Irina and SURMOUNT-1 Investigators, SURMOUNT-1 Investigators},
  title = {Tirzepatide for Obesity Treatment and Diabetes Prevention},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {10},
  pages = {958--971},
  doi = {10.1056/nejmoa2410819}
}
Kostenlos starten →